Payment overview · 2025
General Payments
$182.85
8 reported records · 3 companies
Healthcare provider profile · identity verified
Larry Penick, MD
Allopathic & Osteopathic Physicians|Family Medicine · EAST BERNARD, TX · NPI 1528037579
Verified facts
What the public records show
CMS Open Payments records show Larry Penick, MD received $182.85 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 77.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.52 | 77.9% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.64 | 11.8% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.69 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $182.85 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $131.90 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $113.34 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 377 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 89 |
| Lisinopril | Lisinopril | 272 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 63 |
| Losartan Potassium | Losartan Potassium | 224 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 40 |
| Gabapentin | Gabapentin | 157 | 43 |
| Omeprazole | Omeprazole | 152 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 146 | 27 |
| Metformin Hcl | Metformin Hcl | 146 | 37 |
| Temazepam | Temazepam | 144 | 28 |
| Tramadol Hcl | Tramadol Hcl | 137 | 39 |
| Furosemide | Furosemide | 124 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 35 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 116 | 26 |
| Methylprednisolone | Methylprednisolone | 110 | 92 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 109 | 87 |
| Carvedilol | Carvedilol | 109 | 23 |
| Clonazepam | Clonazepam | 109 | 27 |
| Allopurinol | Allopurinol | 100 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 26 |
| Metformin Hcl Er | Metformin Hcl | 90 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 88 | 32 |
| Alprazolam | Alprazolam | 86 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 21 |
| Ozempic | Semaglutide | 77 | 15 |
| Eliquis | Apixaban | 76 | 14 |
| Simvastatin | Simvastatin | 73 | 21 |
| Potassium Chloride | Potassium Chloride | 72 | 21 |
| Januvia | Sitagliptin Phosphate | 69 | suppressed |
| Meloxicam | Meloxicam | 67 | 15 |
| Montelukast Sodium | Montelukast Sodium | 67 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 14 |
| Sertraline Hcl | Sertraline Hcl | 66 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 16 |
| Jardiance | Empagliflozin | 60 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 17 |
| Finasteride | Finasteride | 54 | 11 |
| Pregabalin | Pregabalin | 52 | 12 |
| Glipizide Er | Glipizide | 51 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Linzess | Linaclotide | 45 | 13 |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 25 |
| Valsartan | Valsartan | 39 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 11 |
| Cephalexin | Cephalexin | 35 | 31 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 11 |
| Amoxicillin | Amoxicillin | 31 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 12 |
| Rybelsus | Semaglutide | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 20 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 27 | 27 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 16 |
| Azithromycin | Azithromycin | 24 | 22 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 14 |
| Cefdinir | Cefdinir | 21 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 11 |
| Ramipril | Ramipril | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Prednisone | Prednisone | 17 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 11 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $182.85 · 8 records | ABBVIE INC. | NUZYRA, QULIPTA, REXULTI, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error